Shimada et al. [66] reached a similar conclusion that serum p53 antibody in ESCC was superior to serological CEA, SCC and CYFRA21-1 biomarkers, and helpful to predict tumor recurrence and metastasis and monitor residual tumor cells. This evidence concerns the gene TP53 and neoplasm.